Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 11/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024170 | 0.84 | TAS1R3 (0.46) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL10024169 | 0.84 | TAS1R3 (0.46) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL10024167 | 0.68 | L3MBTL1 (0.47) | NPC1RAB9AMEN1KMT2ATAS1R3 | |
| SCHEMBL3472930 | 0.68 | PLAU (0.58) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL6018683 | 0.68 | MEN1 (0.45) | MAPTMEN1KMT2ALMNATSHR | |
| SCHEMBL16254042 | 0.67 | HTR1A (0.39) | NPC1RAB9AMEN1KMT2ATAS1R3 | |
| SCHEMBL6018771 | 0.67 | CXCR5 (0.37) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL6243822 | 0.67 | CXCR5 (0.37) | NPC1MAPTRAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6018686 | 0.67 | PLAU (0.57) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL27139434 | 0.67 | MEN1 (0.47) | MAPTMEN1KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895732-B2 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895732-B2 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20120016121-A1 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016121-A1 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | RER1, ABCB11, SLC67A1 | NPC1 1047/4885MAPT 4094/4885RAB9A 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.